Novo Nordisk is also pairing the long-acting insulin with its once-weekly GLP-1 agonist semaglutide in the COMBINE trials programme, which is due to complete in 2024, is also working on a glucose ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

The last few years have been tough for the insulin market, with recent policies and high-level pressure forcing companies to ...

South Africa's competition watchdog is investigating drugmakers Novo Nordisk and Sanofi over possible anti-competitive ...

Novo Nordisk A/S and Sanofi are facing an investigation in South Africa over concerns about potential anti-competitive practices in the human insulin pen market.

During a hearing, representatives for the Newsom administration said they could not provide a timeline for when ...

Pharmac is seeking public feedback on a proposal to fund a new, additional type of insulin for people with diabetes from 1 May 2025. The new medicine (branded as Ryzodeg) is a combination of two other ...

Investing.com -- Novo Nordisk ... Petrelintide is a long-acting amylin analogue, a class of drugs that mimic the hormone amylin, which is released alongside insulin. While the first generation ...

South Africa's competition watchdog is investigating drugmakers Novo Nordisk and Sanofi over possible anti-competitive practices in the human insulin pen market, the authority said on Tuesday.

Investing.com -- Novo Nordisk (CSE: NOVOb) (NYSE: NVO) shares slumped Wednesday after Roche (SIX: ROG) struck a $5.3 billion ...